Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
Pfizer secures patent win at UK High Court in RSV vaccine race
The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving Pfizer, as both companies battle to become the first to launch an RSV vaccine on the UK market.
RSV Vaccine Sales Dip as Target Age Group Narrows in U.S.
RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting millions. Demand has decreased significantly during the autumn vaccination season,
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
HSA approves Pfizer’s new RSV vaccine
This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical protection to infants and seniors
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.
Why Pfizer Will Find It Hard to Appease Its Activist Investor
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
GSK Arexvy protects from RSV over three full seasons
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...
STAT4d
After a rocky debut for new RSV tools, hopes are high as a new season approaches
Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Making an RSV Vaccine Was Hard. Getting People to Take It Is Even Harder
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...
Benzinga.com1d
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Pfizer's legal win invalidates two GSK patents in UK RSV vaccine case. On Monday, Pfizer Inc. PFE stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro.
pharmaphorum6d
Pfizer seeks to overturn three RSV vaccine patents held by GSK
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...
Activist investor Starboard Value takes $1 bln stake in Pfizer, sources say
Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer and wants the U.S. drug giant to make ...